SPY734.37+0.19%QQQ657.57+1.63%BTC/USD75,657.13−0.41%DIA509.30−0.97%GLD369.51−1.59%TLT81.89−0.05%
BenzingaPremium Services
Premium Services
Benzinga News-desk

Benzinga News-desk

Benzinga Staff Writer

Articles by Benzinga News-desk

QUICK SPARK: DEA Judge Pauses Marijuana Rescheduling Hearing over Federal Process Gaps
QUICK SPARK: DEA Judge Pauses Marijuana Rescheduling Hearing over Federal Process Gaps
GAO report flags gaps in federal drug-scheduling procedures; DEA must respond on reopening record.
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Quick Spark: Trump Signs Landmark US-Saudi Nuclear Deal, Expanding Civilian Energy Partnership
Quick Spark: Trump Signs Landmark US-Saudi Nuclear Deal, Expanding Civilian Energy Partnership
Landmark nuclear deal between Trump and Saudi Crown Prince finalized, allowing development of US-backed energy program and opening opportunities for American companies.
AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival
AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS)
Triller Issues Shareholder Letter Of AGM Outcomes, Changes The Company’s Name From Triller Group To Eight Holdings; Gets Shareholder Authorization For A Reverse Stock Split At A Ratio Of No More Than 1-for-10 Within One Year
Triller Issues Shareholder Letter Of AGM Outcomes, Changes The Company’s Name From Triller Group To Eight Holdings; Gets Shareholder Authorization For A Reverse Stock Split At A Ratio Of No More Than 1-for-10 Within One Year
2025 was the reset. 2026 is the monetization year. We shut down what was not working, preserved the assets that matter, restored the public-company platform, and are now focused on converting users, fans, creators,
Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index
Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today
US Launches Strikes On Iran Military Targets After Commercial Ship Attack In Strait Of Hormuz
US Launches Strikes On Iran Military Targets After Commercial Ship Attack In Strait Of Hormuz
U.S. retaliates against Iran for alleged drone attack on cargo ship in Strait of Hormuz, targeting military sites. Tensions in Persian Gulf rise.
Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B Vs $2.594B Est., And Adjusted EBITDA Of $190M-$220M
Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B Vs $2.594B Est., And Adjusted EBITDA Of $190M-$220M
2026 Financial GuidanceThe Company reiterates its guidance for the full year 2026, targeting revenues in the range of $2,550 million to $2,650 million and adjusted EBITDA in the range of $190 million to $220 million.
Cosmos Health’s Cana Laboratories Advances International Patent Application For Proprietary Hydrogel Weight Management Platform Into European Regional Phase And National Phases In US, Australia, And Canada
Cosmos Health’s Cana Laboratories Advances International Patent Application For Proprietary Hydrogel Weight Management Platform Into European Regional Phase And National Phases In US, Australia, And Canada
Building on Its Recent Acquisition of the CCX0722 Intellectual Property, Cosmos Health Owns the Technology Outright and Is Now Pursuing Patent Protection Across Four Major Healthcare Markets Within the $190+ Billion
Shares of crypto-linked stocks are trading lower amid a continued selloff as Bitcoin prices drop. Weakness in the digital token may be connected to a decline in Strategy's STRC high-yielding preferred stock.
Shares of crypto-linked stocks are trading lower amid a continued selloff as Bitcoin prices drop. Weakness in the digital token may be connected to a decline in Strategy's STRC high-yielding preferred stock.
Shares of crypto-linked stocks are trading lower amid a continued selloff as Bitcoin prices drop. Weakness in the digital token may be connected to a decline in Strategy’s STRC high-yielding preferred stock.
Google Introducing Computer Use In Gemini 3.5 Flash
Google Introducing Computer Use In Gemini 3.5 Flash
https://blog.google/innovation-and-ai/models-and-research/gemini-models/introducing-computer-use-gemini-3-5-flash/
Clive Davis, Grammy-Award Winning Producer, Music Executive Known As “The Man With The Golden Ear,” Dies At 94
Clive Davis, Grammy-Award Winning Producer, Music Executive Known As “The Man With The Golden Ear,” Dies At 94
Clive Davis, one of the most influential and iconic figures in the history of music, passed away on June 22 at his New York City home, Variety confirmed. He was 94.  Davis had recently been hospitalized with an upper
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026
Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
Trump Unveils Iran Peace Framework As Questions Remain Over Long-Term Stability
Trump Unveils Iran Peace Framework As Questions Remain Over Long-Term Stability
Trump defends Iran agreement to reopen shipping lanes, end conflict and blockades, while Iran pledges no nukes and U.S. eases sanctions, with $300B fund.
House Votes To Restrict Trump's Military Authority In Iran
House Votes To Restrict Trump's Military Authority In Iran
House approves war powers resolution limiting Trump's authority to continue military operations against Iran without congressional approval.
Kevin Warsh Confirmed As Next Federal Reserve Chair
Kevin Warsh Confirmed As Next Federal Reserve Chair
Kevin Warsh faces the challenge of balancing inflation and growth while maintaining Fed's independence.
Ted Turner, Entrepreneur Who Founded CNN, Won The America's Cup, Dies At 87
Ted Turner, Entrepreneur Who Founded CNN, Won The America's Cup, Dies At 87
Known for his brash nature, Ted Turner founded CNN and other media channels, but his career took a hit after the AOL Time Warner merger. He was also an avid sailor, competing in the America's Cup.
Trump Labor Secretary Lori Chavez-DeRemer Resigns During Misconduct Probe, Third Cabinet Exit
Trump Labor Secretary Lori Chavez-DeRemer Resigns During Misconduct Probe, Third Cabinet Exit
Labor Secretary Lori Chavez-DeRemer resigns amidst misconduct allegations, becoming third Cabinet-level departure under Trump's second term.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved